Edward Jolyon Griffen
AstraZeneca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Edward Jolyon Griffen.
Drug Discovery Today | 2013
Alexander G. Dossetter; Edward Jolyon Griffen; Andrew G. Leach
Multiple parameter optimisation in drug discovery is difficult, but Matched Molecular Pair Analysis (MMPA) can help. Computer algorithms can process data in an unbiased way to yield design rules and suggest better molecules, cutting the number of design cycles. The approach often makes more suggestions than can be processed manually and methods to deal with this are proposed. However, there is a paucity of contextually specific design rules, which would truly make the technique powerful. By combining extracted information from multiple sources there is an opportunity to solve this problem and advance medicinal chemistry in a matter of months rather than years.
Journal of Chemical Information and Modeling | 2010
Daniel Jon Warner; Edward Jolyon Griffen; Stephen A. St-Gallay
An algorithm to automatically identify and extract matched molecular pairs from a collection of compounds has been developed, allowing the learning associated with each molecular transformation to be readily exploited in drug discovery projects. Here, we present the application to an example data set of 11 histone deacetylase inhibitors. The matched pairs were identified, and corresponding differences in activity and lipophilicity were recorded. These property differences were associated with the chemical transformations encoded in the SMIRKS reaction notation. The transformations identified a subseries with the optimal balance of these two parameters. Enumeration of a virtual library of compounds using the extracted transformations identified two additional compounds initially excluded from the analysis with an accurate estimation of their biological activity. We describe how the WizePairZ system can be used to archive and apply medicinal chemistry knowledge from one drug discovery project to another as well as identify common bioisosteres.
Bioorganic & Medicinal Chemistry Letters | 2011
Kate M. Clapham; Julia Bardos; M. Raymond V. Finlay; Bernard T. Golding; Edward Jolyon Griffen; Roger J. Griffin; Ian R. Hardcastle; Keith Menear; Attilla Ting; Paul Turner; Gail L. Young; Celine Cano
Introduction of an O-alkoxyphenyl substituent at the 8-position of the 2-morpholino-4H-chromen-4-one pharmacophore enabled regions of the ATP-binding site of DNA-dependent protein kinase (DNA-PK) to be probed further. Structure-activity relationships have been elucidated for inhibition of DNA-PK and PI3K (p110α), with N-(2-(cyclopropylmethoxy)-4-(2-morpholino-4-oxo-4H-chromen-8-yl)phenyl)-2-morpholinoacetamide 11a being identified as a potent and selective DNA-PK inhibitor (IC(50)=8 nM).
Journal of Medicinal Chemistry | 2015
Helen E. Colley; Munitta Muthana; Sarah Danson; Lucinda V. Jackson; Matthew L. Brett; Joanne Harrison; Sean F. Coole; Daniel P. Mason; Luke R. Jennings; Melanie Wong; Vamshi Tulasi; Dennis Norman; Peter Lockey; Lynne Williams; Alexander G. Dossetter; Edward Jolyon Griffen; Mark J. Thompson
A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics.
Journal of Cheminformatics | 2011
Daniel J. Warner; Stephen A. St-Gallay; Edward Jolyon Griffen
An algorithm to automatically identify and extract matched molecular pairs from a collection of compounds has been developed, allowing the learning associated with each molecular transformation to be readily exploited in drug discovery projects. Here, we present the application to an example data set of 11 histone deacetylase inhibitors. The matched pairs were identified, and corresponding differences in activity and lipophilicity were recorded. These property differences were associated with the chemical transformations encoded in the SMIRKS reaction notation. The transformations identified a subseries with the optimal balance of these two parameters. Enumeration of a virtual library of compounds using the extracted transformations identified two additional compounds initially excluded from the analysis with an accurate estimation of their biological activity. We describe how the WizePairZ system can be used to archive and apply medicinal chemistry knowledge from one drug discovery project to another as well as identify common bioisosteres.
Drug Discovery Today | 2018
Edward Jolyon Griffen; Alexander G. Dossetter; Andrew G. Leach; Shane Montague
AI comes to lead optimization: medicinal chemistry in all disease areas can be accelerated by exploiting our pre-competitive knowledge in an unbiased way.
Journal of Chemical Information and Modeling | 2017
Iva Lukac; Joanna Zarnecka; Edward Jolyon Griffen; Alexander G. Dossetter; Stephen A. St-Gallay; Steven J. Enoch; Judith C. Madden; Andrew G. Leach
We have applied the two most commonly used methods for automatic matched pair identification, obtained the optimum settings, and discovered that the two methods are synergistic. A turbocharging approach to matched pair analysis is advocated in which a first round (a conservative categorical approach that uses an analogy with coin flips, heads corresponding to an increase in a measured property, tails to a decrease, and a biased coin to a structural change that reliably causes a change in that property) provides the settings for a second round (which uses the magnitude of the change in properties). Increased chemical specificity allows reliable knowledge to be extracted from smaller sets of pairs, and an assay-specific upper limit can be placed on the number of pairs required before adequate sampling of variability has been achieved.
Reference Module in Chemistry, Molecular Sciences and Chemical Engineering#R##N#Comprehensive Medicinal Chemistry III | 2017
Andrew G. Leach; Iva Lukac; J.M. Zarnecka; Alexander G. Dossetter; Edward Jolyon Griffen
The aim of this article is to highlight the areas in which matched molecular pair analysis has progressed in the last decade and new directions and challenges that are currently being addressed.
Archive | 2007
Sam Butterworth; Edward Jolyon Griffen; Martin Pass
Archive | 2005
Malena Bengtsson; Joakim Larsson; Grigorios Nikitidis; Peter Storm; John Peter Bailey; Edward Jolyon Griffen; Jean-Claude Arnould; Thomas Geoffrey Colerick Bird